Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer.
In this episode of In the Headlines, Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, discuss the “doomsday scenario” facing academic cancer centers that would follow the success of President Trump’s move to limit indirect costs to 15% for NIH-funded institutions.
Introducing The Cancer Letter Podcast—a weekly podcast featuring interviews, discussions, and more to dig deep into the issues that shape oncology.
